{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:50:51Z","timestamp":1792662651934,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2007,7,5]],"date-time":"2007-07-05T00:00:00Z","timestamp":1183593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Novel therapeutic strategies for hemophilia must be at least as effective as current treatments and demonstrate long-term safety. To date, several small clinical trials of hemophilia gene transfer have failed to show the promise of preclinical evaluations. Therefore, we wanted to develop and evaluate the feasibility of a novel ex vivo gene transfer strategy whereby cells derived from progenitor cells are engineered to express factor VIII (FVIII) and then implanted subcutaneously to act as a depot for FVIII expression. Circulating blood outgrowth endothelial cells (BOECs) were isolated from canine and murine blood and transduced with a lentiviral vector encoding the canine FVIII transgene. To enhance safety, these cells were implanted subcutaneously in a Matrigel scaffold, and the efficacy of this strategy was compared with i.v. delivery of engineered BOECs in nonhemophilic nonobese diabetic\/severe combined immunodeficiency mice. Therapeutic levels of FVIII persisted for 15 weeks, and these levels of stable expression were extended to 20 weeks when the cytomegalovirus promoter was replaced with the thrombomodulin regulatory element. Subsequent studies in immunocompetent hemophilic mice, pretreated with tolerizing doses of FVIII or with transient immunosuppression, showed therapeutic FVIII expression for 27 weeks before the eventual return to baseline levels. This loss of transgene expression appears to be due to the disappearance of the implanted cells. The animals treated with either of the two tolerizing regimens did not develop anti-FVIII antibodies. Biodistribution analysis demonstrated that BOECs were retained inside the subcutaneous implants. These results indicate, for the first time, that genetically modified endothelial progenitor cells implanted in a subcutaneous scaffold can provide sustained therapeutic levels of FVIII and are a promising and safe treatment modality for hemophilia A.<\/jats:p>\n               <jats:p>Disclosure of potential conflicts of interest is found at the end of this article.<\/jats:p>","DOI":"10.1634\/stemcells.2006-0699","type":"journal-article","created":{"date-parts":[[2007,7,6]],"date-time":"2007-07-06T02:21:08Z","timestamp":1183688468000},"page":"2660-2669","source":"Crossref","is-referenced-by-count":82,"title":["Ex Vivo Gene Therapy for Hemophilia A That Enhances Safe Delivery and Sustained In Vivo Factor VIII Expression from Lentivirally Engineered Endothelial Progenitors"],"prefix":"10.1093","volume":"25","author":[{"given":"Hideto","family":"Matsui","sequence":"first","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Kashihara City, Nara, Japan"},{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Labelle","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Hegadorn","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandler","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hebbel","sequence":"additional","affiliation":[{"name":"Vascular Biology Center and Division of Hematology Oncology Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Galipeau","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hough","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,7,5]]},"reference":[{"key":"2022011307320667600_bib1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/312326a0","article-title":"Characterization of the human factor VIII gene","volume":"312","author":"Gitschier","year":"1984","journal-title":"Nature"},{"key":"2022011307320667600_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-2004-825638","article-title":"Clinical gene transfer studies for hemophilia A","volume":"30","author":"Chuah","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"2022011307320667600_bib3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1538-7836.2005.01401.x","article-title":"Gene therapy for hemophilia: An imperative to succeed","volume":"3","author":"Hough","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2022011307320667600_bib4","doi-asserted-by":"crossref","first-page":"9973","DOI":"10.1073\/pnas.96.18.9973","article-title":"Gene therapy for the hemophilias","volume":"96","author":"Kay","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011307320667600_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2516.2002.00646.x","article-title":"Gene therapy: Reality or myth for the global bleeding disorders community?","volume":"8","author":"Kelley","year":"2002","journal-title":"Haemophilia"},{"key":"2022011307320667600_bib6","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"key":"2022011307320667600_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2004-825632","article-title":"Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: Preclinical studies","volume":"30","author":"Van Damme","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"2022011307320667600_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/1566523013348508","article-title":"Viral vector-mediated gene therapy for hemophilia","volume":"1","author":"VandenDriessche","year":"2001","journal-title":"Curr Gene Ther"},{"key":"2022011307320667600_bib9","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2002-03-0823","article-title":"Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors","volume":"101","author":"Chuah","year":"2003","journal-title":"Blood"},{"key":"2022011307320667600_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-2004-825631","article-title":"Preclinical gene therapy studies for hemophilia using adenoviral vectors","volume":"30","author":"Thorrez","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"2022011307320667600_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2003-05-1426","article-title":"Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A","volume":"103","author":"Brown","year":"2004","journal-title":"Blood"},{"key":"2022011307320667600_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1538-7836.2004.00552.x","article-title":"Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice","volume":"2","author":"Brown","year":"2004","journal-title":"J Thromb Haemost"},{"key":"2022011307320667600_bib13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ymthe.2004.08.006","article-title":"Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells","volume":"10","author":"Moayeri","year":"2004","journal-title":"Mol Ther"},{"key":"2022011307320667600_bib14","doi-asserted-by":"crossref","first-page":"10379","DOI":"10.1073\/pnas.96.18.10379","article-title":"Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice","volume":"96","author":"VandenDriessche","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011307320667600_bib15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1525-0016(03)00073-X","article-title":"Efficient production of human FVIII in hemophilic mice using lentiviral vectors","volume":"7","author":"Kootstra","year":"2003","journal-title":"Mol Ther"},{"key":"2022011307320667600_bib16","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2004-11-4358","article-title":"Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer","volume":"106","author":"Kang","year":"2005","journal-title":"Blood"},{"key":"2022011307320667600_bib17","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2004-12-4736","article-title":"Novel lentiviral vectors displaying \u201cearly-acting cytokines\u201d selectively promote survival and transduction of NOD\/SCID repopulating human hematopoietic stem cells","volume":"106","author":"Verhoeyen","year":"2005","journal-title":"Blood"},{"key":"2022011307320667600_bib18","first-page":"137","article-title":"Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo","volume":"3","author":"Yang","year":"1996","journal-title":"Gene Ther"},{"key":"2022011307320667600_bib19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2001-11-0067","article-title":"Dangerous liaisons: The role of \u201cdanger\u201d signals in the immune response to gene therapy","volume":"100","author":"Brown","year":"2002","journal-title":"Blood"},{"key":"2022011307320667600_bib20","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood.V94.12.3968.424k43_3968_3975","article-title":"Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity","volume":"94","author":"Lozier","year":"1999","journal-title":"Blood"},{"key":"2022011307320667600_bib21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2174\/1566523034578113","article-title":"Biosafety of onco-retroviral vectors","volume":"3","author":"VandenDriessche","year":"2003","journal-title":"Curr Gene Ther"},{"key":"2022011307320667600_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ymthe.2005.07.358","article-title":"Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice","volume":"12","author":"Themis","year":"2005","journal-title":"Mol Ther"},{"key":"2022011307320667600_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/hum.1998.9.3-353","article-title":"Bone marrow stromal cells as targets for gene therapy of hemophilia A","volume":"9","author":"Chuah","year":"1998","journal-title":"Hum Gene Ther"},{"key":"2022011307320667600_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/10430340050015626","article-title":"Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice","volume":"11","author":"Chuah","year":"2000","journal-title":"Hum Gene Ther"},{"key":"2022011307320667600_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2516.2003.00709.x","article-title":"Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats","volume":"9","author":"Van Damme","year":"2003","journal-title":"Haemophilia"},{"key":"2022011307320667600_bib26","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1634\/stemcells.2003-0106","article-title":"Efficient Lentiviral Transduction And Improved Engraftment Of Human Bone Marrow Mesenchymal Cells","volume":"24","author":"Van Damme","year":"2006","journal-title":"Stem Cells"},{"key":"2022011307320667600_bib27","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","article-title":"Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A","volume":"344","author":"Roth","year":"2001","journal-title":"N Engl J Med"},{"key":"2022011307320667600_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1172\/JCI8071","article-title":"Origins of circulating endothelial cells and endothelial outgrowth from blood","volume":"105","author":"Lin","year":"2000","journal-title":"J Clin Invest"},{"key":"2022011307320667600_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.V99.2.457","article-title":"Use of blood outgrowth endothelial cells for gene therapy for hemophilia A","volume":"99","author":"Lin","year":"2002","journal-title":"Blood"},{"key":"2022011307320667600_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V100.3.813","article-title":"Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo","volume":"100","author":"VandenDriessche","year":"2002","journal-title":"Blood"},{"key":"2022011307320667600_bib31","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1089\/10430340260201671","article-title":"The canine factor VIII 3\u2032-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo","volume":"13","author":"Notley","year":"2002","journal-title":"Hum Gene Ther"},{"key":"2022011307320667600_bib32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1089\/104303403322319372","article-title":"Comparison of transfection conditions for a lentivirus vector produced in large volumes","volume":"14","author":"Karolewski","year":"2003","journal-title":"Hum Gene Ther"},{"key":"2022011307320667600_bib33","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/sj.gt.3302094","article-title":"Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain","volume":"10","author":"Baekelandt","year":"2003","journal-title":"Gene Ther"},{"key":"2022011307320667600_bib34","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.gt.3301731","article-title":"Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods","volume":"9","author":"Sastry","year":"2002","journal-title":"Gene Ther"},{"key":"2022011307320667600_bib35","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1093\/nar\/19.15.4293","article-title":"Simplified mammalian DNA isolation procedure","volume":"19","author":"Laird","year":"1991","journal-title":"Nucleic Acids Res"},{"issue":"(Suppl 1)","key":"2022011307320667600_bib36","article-title":"Characterization of canine factor VIII and quantitative determination in canine plasma.","volume":"3","author":"Shibata","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2022011307320667600_bib37","first-page":"612","article-title":"Proceedings: A more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb Diath Haemorrh"},{"key":"2022011307320667600_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10623320601177254","article-title":"Distribution of circulation-derived endothelial progenitors following systemic delivery","volume":"14","author":"Smits","year":"2007","journal-title":"Endothelium"},{"key":"2022011307320667600_bib39","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.79.17.11434-11442.2005","article-title":"Large-scale analysis of adeno-associated virus vector integration sites in normal human cells","volume":"79","author":"Miller","year":"2005","journal-title":"J Virol"},{"key":"2022011307320667600_bib40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-FIX and limitation imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"2022011307320667600_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"2022011307320667600_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked choronic granulomatous disease by gene therapy, augmented by insertional activation by MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Otto","year":"2006","journal-title":"Nat Med"},{"key":"2022011307320667600_bib43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat Biotechnol"},{"key":"2022011307320667600_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"2022011307320667600_bib45","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2005-11-4571","article-title":"FVIII production by human lung microvascular endothelial cells","volume":"108","author":"Jacquemin","year":"2006","journal-title":"Blood"},{"key":"2022011307320667600_bib46","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI28416","article-title":"Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies","volume":"116","author":"Shi","year":"2006","journal-title":"J Clin Invest"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Fstemcells.2006-0699","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/stemcells.2006-0699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/stemcells.2006-0699","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/25\/10\/2660\/41963610\/stmcls_25_10_2660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/25\/10\/2660\/41963610\/stmcls_25_10_2660.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:53:09Z","timestamp":1642560789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/25\/10\/2660-2669\/6402702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,5]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2007,7,5]]},"published-print":{"date-parts":[[2007,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/stemcells.2006-0699","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,10,1]]},"published":{"date-parts":[[2007,7,5]]}}}